Hepatitis A vaccination in Iran: an evidence-to-recommendations synthesis using a WHO-aligned framework
Improved water, sanitation, and hygiene (WASH) have shifted hepatitis A virus (HAV) infection in Iran to older ages, when illness is more symptomatic and severe. Inactivated hepatitis A (HepA) vaccines are safe and effective, but Iran has no routine HepA vaccination; policy decisions must balance burden, economics, and feasibility. We conducted a Ministry of Health–commissioned evidence-to-recommendations (EtR) process integrating WHO (2022) and ACIP MMWR (2006/2020) guidance, Iranian sero-epidemiology, and evidence on burden, vaccine performance, cost-effectiveness, and implementation. Iran has transitioned to low endemicity: immunity is high among older adults, but susceptible cohorts remain among children, adolescents, and young adults, varying by province and socioeconomic strata. Available Iranian clinical data indicate that hepatitis A continues to cause clinically significant disease and hospitalization, although national estimates are limited; international evidence indicates greater severity among adults, particularly those with chronic liver disease or other comorbidities. Both licensed vaccine types, inactivated and live-attenuated, are highly effective and safe. The EtR panel considered both and based its recommendations on inactivated vaccines, because they are available in Iran, provide durable protection after 2 doses, and are suitable for immunocompromised persons, pregnant women, and PEP. Economic analyses generally support universal childhood vaccination mainly where incidence or outbreak risk is high; targeted vaccination is more favorable in low-endemic settings. Given Iran’s current epidemiologic profile, health-system context, and available economic evidence, while recognizing important gaps in national clinical and cost data, universal routine childhood vaccination was not prioritized; targeted vaccination and vaccine use for post-exposure prophylaxis (PEP) and outbreak control showed greater potential net benefit. EtR judgments support targeted HepA vaccination with inactivated vaccine for: (i) chronic liver disease and selected immunocompromising conditions; (ii) exposure-risk networks (e.g., drug use, homelessness, prisoners, some occupations); and (iii) outbreak, disaster, or humanitarian settings, alongside surveillance and PEP. Universal routine childhood vaccination is not supported at this time. Periodic reassessment is recommended as new sero-epidemiologic and economic data emerge.
Authors
- Babak Eshrati (ORCID: https://orcid.org/0000-0001-5999-7173)
- Ebrahim Babaee (ORCID: https://orcid.org/0000-0001-7969-9122)
- Mona Roozbehani (ORCID: https://orcid.org/0000-0002-8016-0973)
- Mahdi Roostaei (ORCID: https://orcid.org/0000-0002-9568-0816)
- Mahdi Soheyli (ORCID: https://orcid.org/0009-0002-6543-5075)
- Mahdi Hashempour
Institutions
- Iran University of Medical Sciences (IR)
- Tehran University of Medical Sciences (IR)
Publication Details
- Journal
- BMC Health Services Research
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1186/s12913-026-16182-7
- Primary Topic
- Hepatitis Viruses Studies and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00